Biosimilars and Biologics Market Size, Share Analysis, Growth Trends and Forecast 2026-2033

Biosimilars and Biologics Market Overview

The global demand for biosimilars and biologics is robust. It continues to grow, driven by the increasing prevalence of chronic diseases, aging populations, technological advancements, and efforts to make healthcare more affordable. For instance, by the end of 2024, the FDA approved a total of 71 biosimilars, including six follow-on biologicals that did not undergo the BLA 351K process for use in the US. These novel product launches are boosting the market growth by offering a huge number of biosimilars.

List of recently FDA-approved biosimilar products:

Executive Summary

For more details on this report – Request for Sample

Biosimilars and Biologics Market Dynamics: Drivers & Restraints

Rising aging populations and chronic disease burden are significantly driving the biosimilars and biologics market growth

As populations age, the prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders increases. These conditions often require long-term, specialized treatments, and biosimilars and biologics offer targeted and effective therapies for many of these diseases. The high efficacy of biologics and biosimilars in treating complex chronic conditions creates strong demand as the global elderly population grows.

For instance, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. This aging population drives up the demand for biologics as a primary treatment option, expanding the market size. At the same time, this demographic’s high treatment needs exert financial pressure on healthcare systems, leading to an increased emphasis on cost-saving alternatives, such as biosimilars, once the original biologics’ patents expire.

Regulatory challenges are hampering the market growth

Regulatory challenges pose significant barriers to the growth of the biosimilars and biologics markets. These challenges stem from complex approval processes, differing regulations across regions, and stringent requirements that can delay market entry and increase costs. Unlike generics, biosimilars are required to undergo rigorous clinical testing to demonstrate safety, efficacy, and biosimilarity to their reference biologics. 

Regulatory bodies like the FDA and EMA demand comprehensive evidence, including analytical, animal, and clinical data, to ensure biosimilars are comparable to original biologics. This approval process can be lengthy and costly, often requiring several years to complete.

In the United States, the FDA’s Biologics Price Competition and Innovation Act (BPCIA) provides a pathway for biosimilar approval, but the process remains time-consuming and expensive. For instance, Sandoz’s Zarxio (filgrastim-sndz) took about four years from initial development to FDA approval as the first U.S.-approved biosimilar. These extended timelines can delay market entry, limit the availability of biosimilars, and discourage investment in biosimilar development due to high upfront costs.

Biosimilars and Biologics Market Segmentation Analysis

The global biosimilars and biologics market is segmented based on type, application, and region.

Increasing Demand for Innovative Biologic Therapies Drives the Biologics Segment

The biologics segment holds a significant share of the global biosimilars and biologics market, driven by the widespread adoption of monoclonal antibodies, recombinant proteins, vaccines, and other advanced biologic therapies for the treatment of complex and chronic diseases. Biologics have transformed the management of conditions such as cancer, autoimmune disorders, and rare diseases by offering targeted mechanisms of action, improved clinical outcomes, and personalized treatment approaches. Continued investments in biologics research, expanding regulatory approvals, and increasing adoption of precision medicine continue to support the segment's market leadership.

Reflecting this trend, leading biopharmaceutical companies are expanding their biologics portfolios through product innovation and strategic investments. Ongoing advancements in next-generation biologic therapies, including antibody-drug conjugates, cell and gene therapies, and novel immunotherapies, continue to strengthen the role of biologics across multiple therapeutic areas and support sustained market growth.

Expanding Patent Expirations and Cost-Effective Treatment Options Accelerate the Biosimilars Segment

The biosimilars segment is expected to witness the fastest growth during the forecast period, supported by the increasing expiration of patents for blockbuster biologic drugs and the growing need for affordable treatment alternatives. Biosimilars offer comparable safety, efficacy, and quality to reference biologics while helping reduce healthcare expenditures and improve patient access to advanced therapies. Favorable regulatory pathways, rising physician confidence, and expanding reimbursement support are further encouraging biosimilar adoption across both developed and emerging healthcare markets.

In line with this momentum, pharmaceutical manufacturers continue to strengthen their biosimilar pipelines through strategic collaborations, regulatory approvals, and commercial launches across oncology, immunology, endocrinology, and other therapeutic areas. These developments are expected to accelerate biosimilar penetration and contribute to broader access to biologic treatments worldwide.

List of biosimilars approved for cancer treatment:

Biosimilars and Biologics Market Geographical Analysis

North America Biosimilars and Biologics Market

North America remains one of the largest markets for biosimilars and biologics, supported by strong biotechnology innovation, advanced healthcare infrastructure, robust research investments, and an established regulatory environment.

The United States leads the regional market through significant biologics research, increasing biosimilar approvals, extensive clinical development activities, and strong presence of leading biopharmaceutical companies. Growing demand for cost-effective therapies and increasing prevalence of chronic diseases continue to support market expansion.

Major demand-generating therapeutic areas include:

• Oncology

• Autoimmune Diseases

• Diabetes

• Hematology

• Rare Diseases

• Infectious Diseases

Asia-Pacific Biosimilars and Biologics Market

Asia-Pacific is expected to register the fastest growth during the forecast period due to expanding biotechnology capabilities, increasing healthcare expenditure, supportive government initiatives, and rising demand for affordable biologic therapies.

China remains a major regional market driven by rapid expansion of domestic biopharmaceutical manufacturing, increasing biosimilar approvals, and significant investments in biotechnology innovation.

India is emerging as a major growth opportunity due to:

• Strong biosimilar manufacturing capabilities

• Cost-efficient biologics production

• Expansion of biotechnology research and development

• Growing exports of biosimilars to global markets

• Increasing government support for biotechnology innovation

Japan, South Korea, Australia, and Southeast Asian countries continue investing in advanced biologics research, manufacturing capacity, and regulatory modernization to strengthen regional competitiveness.

Europe Biosimilars and Biologics Market

Europe represents a mature and highly regulated market with widespread biosimilar adoption supported by well-established regulatory pathways, favorable reimbursement policies, and increasing healthcare cost optimization initiatives.

Germany, France, the United Kingdom, Italy, and Spain remain major contributors owing to strong pharmaceutical industries, early biosimilar adoption, and continuous investment in biologic innovation.

The region is increasingly focusing on:

• Expansion of biosimilar utilization

• Development of innovative biologic therapies

• Advanced biomanufacturing capabilities

• Personalized and precision medicine

• Sustainable healthcare expenditure management

These initiatives continue to strengthen Europe's leadership in biologics innovation and biosimilar commercialization.

Latin America Biosimilars and Biologics Market

Latin America is experiencing steady market growth supported by improving healthcare infrastructure, expanding access to biologic medicines, and increasing regulatory harmonization.

Countries such as Brazil, Mexico, Argentina, and Colombia are witnessing growing adoption of biosimilars across oncology, autoimmune diseases, endocrinology, and immunology treatment areas.

Rising investments in healthcare modernization and improving patient access to advanced therapies are expected to support long-term market growth.

Middle East & Africa Biosimilars and Biologics Market

The Middle East & Africa region is witnessing increasing demand for biosimilars and biologics due to improving healthcare infrastructure, rising prevalence of chronic diseases, expanding pharmaceutical investments, and government initiatives to enhance access to advanced therapies.

Saudi Arabia, the United Arab Emirates, and South Africa are leading regional investments in biotechnology, pharmaceutical manufacturing, and healthcare modernization.

Biosimilars and Biologics Market Competitive Landscape

Top companies in the biosimilars and biologics market include Amgen Inc., Johnson & Johnson, Biogen Inc., Teva Pharmaceutical Industries Limited, Biocon Biologics Inc., Pfizer Inc., Celltrion, Inc., Samsung Bioepis, AbbVie Inc., Boehringer Ingelheim International GmbH, and among others. The emerging players in the market include Eli Lilly and Company, Sanofi S.A., Fresenius Kabi AG, Coherus BioSciences Inc., Alvotech S.A., Polpharma Biologics S.A., Formycon AG, and Hexal AG, among others.

Key Takeaways

• The increasing adoption of biosimilars is emerging as a key industry trend, driven by the growing need to reduce healthcare costs while expanding patient access to high-quality biologic therapies across oncology, autoimmune, diabetes, and other chronic disease indications.
• North America maintains a leading position in the global biosimilars and biologics market, supported by advanced healthcare infrastructure, high biologics adoption, strong research and development capabilities, favorable reimbursement frameworks, and the presence of major biopharmaceutical companies.
• Asia-Pacific is projected to record significant growth as expanding healthcare access, increasing investments in biopharmaceutical manufacturing, supportive regulatory reforms, and rising demand for affordable biologic therapies continue to accelerate market development across emerging economies.
• Patent expirations of several blockbuster biologic drugs are becoming a major market catalyst, creating substantial opportunities for biosimilar manufacturers to introduce cost-effective alternatives and intensify competition across multiple therapeutic categories.
• The growing prevalence of chronic diseases, including cancer, autoimmune disorders, diabetes, and inflammatory conditions, is increasing demand for innovative biologics and biosimilars that offer improved clinical outcomes and expanded treatment accessibility.
• Industry participants are increasingly prioritizing investments in advanced biomanufacturing technologies, strategic partnerships, regulatory expertise, and robust biosimilar development pipelines to strengthen market competitiveness and long-term growth.
• Rising investments in biologics research, next-generation antibody therapies, cell and gene therapies, biosimilar commercialization, and global manufacturing capacity expansion are creating significant opportunities for biopharmaceutical companies and contract development and manufacturing organizations worldwide.

Biosimilars and Biologics Market Scope

Key Developments of the Biosimilars and Biologics Market

• June 2026: Teva Pharmaceutical Industries launched AHZANTIVE® (aflibercept), an EMA-approved biosimilar to Eylea®, expanding its European ophthalmology biosimilars portfolio. The launch strengthens Teva's biologics strategy by improving patient access to retinal disease therapies and broadening its biosimilar footprint across Europe.

• January 2026: Biocon Biologics announced the expansion of its oncology biosimilar pipeline with proposed biosimilars for nivolumab, pembrolizumab, and trastuzumab/hyaluronidase. The company also outlined its strategic integration with Biocon Ltd. to reinforce global leadership in biosimilars, biologics manufacturing, and next-generation oncology innovation.
• December 2025: Zentiva entered the biologics segment with the EU-wide launch of its first monoclonal antibody biosimilar following European regulatory approval. The milestone marked the company's expansion beyond conventional generics, strengthening its long-term biologics strategy and improving access to affordable biological medicines across Europe.
• December 2025: Biocon Biologics expanded its biosimilar pipeline by securing global rights to its biosimilar adalimumab and signing a worldwide commercialization agreement for a biosimilar aflibercept. These strategic licensing agreements enhanced the company's ophthalmology and immunology portfolios while accelerating future global commercialization opportunities.

Why Purchase This Report?

The Biosimilars and Biologics Market report provides comprehensive intelligence for biopharmaceutical manufacturers, biotechnology companies, contract development and manufacturing organizations (CDMOs), healthcare providers, investors, regulators, and strategic decision-makers seeking to understand the evolving global biologics landscape and emerging biosimilar opportunities.

• Gain detailed insights into key market drivers, restraints, opportunities, and emerging trends shaping the biologics and biosimilars industry.

• Assess the impact of patent expirations, regulatory pathways, pricing dynamics, and healthcare reimbursement policies on market growth.

• Understand innovation trends across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilar development.

• Evaluate demand patterns across major therapeutic areas, healthcare settings, and regional markets.

• Benchmark leading biopharmaceutical companies, biosimilar developers, strategic collaborations, product approvals, and competitive positioning.

• Identify high-growth opportunities associated with oncology, autoimmune diseases, diabetes, rare diseases, and next-generation biologic therapies.

• Support investment decisions, product development strategies, portfolio expansion, and long-term commercial planning.

The global biosimilars and biologics market report delivers a detailed analysis with 54 key tables, more than 45 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience

• Biopharmaceutical Manufacturers

• Biosimilar Developers

• Biotechnology Companies

• Industry Investors/Investment Bankers

• Research Professionals

• Contract Development and Manufacturing Organizations (CDMOs)

Suggestions for Related Reports

• Biologics Market
• Biosimilars Market
• Biopharmaceuticals Market
• US Biosimilars Market
• Insulin Biosimilars Market